NCT01888796

Diastolic Dysfunction in Patients With Type 2 Diabetes Mellitus

Effect of Linagliptin Therapy on Myocardial Diastolic Function in Patients With Type 2 Diabetes Mellitus

• Status: Terminated
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 8 (actual)
• Sponsor: RWTH Aachen University · Academic / Other
• Sex: All
• Age: 50 Years
• Healthy volunteers: Not accepted

Summary

Examination of the effect of Linagliptin versus placebo on diastolic function in patients with type 2 diabetes mellitus and diastolic dysfunction as assessed by transthoracic echocardiography. Furthermore the effect on serum levels of NT-pro BNP as a biomarker of heart failure will be investigated.

Detailed description

Treatment: The Patients will receive Linagliptin 5 mg QD or placebo for a period of 6 months. The echocardiography and 24h RR measurement will be performed at baseline and 6 months after initiation of the therapy. The blood chemistry (Glucose, HbA1c, BNP) will be evaluated at baseline as well as 3 and 6 months after initiation of the therapy.

Conditions

• Diabetes Mellitus Type 2 (T2DM)
• Left Ventricular Diastolic Dysfunction

Interventions

Type	Name	Description
DRUG	Linagliptin
DRUG	placebo

Timeline

• Start date: 2013-09-01
• Primary completion: 2014-12-01
• Completion: 2014-12-01
• First posted: 2013-06-28
• Last updated: 2017-04-12

Locations

1 site across 1 country: Germany